cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Efta Triastuti
Contact Email
efta.triastuti@ub.ac.id
Phone
+62341-569117
Journal Mail Official
pji@ub.ac.id
Editorial Address
Pharmaceutical Journal of Indonesia Department of Pharmacy, Faculty of Medicine, Brawijaya University Jalan Veteran (Kampus Sumbersari) Malang 65145 Tel. (0341) 569117ext 156, 173 ; Fax. (0341) 564755 Website : http://www.pji.ub.ac.id Email :pji@ub.ac.id
Location
Kota malang,
Jawa timur
INDONESIA
Pharmaceutical Journal of Indonesia
Published by Universitas Brawijaya
ISSN : 2461114X     EISSN : 2461114X     DOI : https://doi.org/10.21776/ub.pji
Core Subject : Health, Science,
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Public Health
Pharmaceutical Journal of Indonesia (PJI) is an online journal which is published twice a year by Department of Pharmacy, Faculty of Medicine, Brawijaya University. The articles published in PJI cover the themes of Clinical and Community Pharmacy, Pharmaceutical Chemistry, Pharmaceutical Technology, and Natural Product Pharmacy/Chemistry.
Arjuna Subject : Pharmacology, Toxicology and Pharmaceutics - Pharmacology, Toxicology and Pharmaceutics (Lain-Lain)
Articles 1 Documents
 1 
Search results for , issue "Vol. 5 No. 1 (2019)" : 1 Documents clear
Cost - Effectiveness Analysis of Chloramphenicol, Ceftriaxone and Cefixime Use in Pediatric Thypoid Fever Patient (Research Conducted at Karsa Husada Batu Hospital) Ni Made Diah Pramesti Dewi; Ratna Kurnia Illahi; Diana Lyrawati
Pharmaceutical Journal of Indonesia Vol. 5 No. 1 (2019)
Publisher : Brawijaya University

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Typhoid fever in Indonesia is still high at 1.6% from 0.3% -3%. Typhoid fever can be treated with several alternative of antibiotic therapy that is chloramphenicol, ceftriaxone and cefixime. This research aimed to analyze the cost-effectiveness the usage of chloramphenicol, ceftriaxone and cefixime antibiotic from health care providers perspective. Medical records and direct medical cost for typhoid fever patients aged 6–12 years were analyzed retrospectively from January 2016–December 2018. Samples were 48 patients and used total sampling method. The usage of chloramphenicol, ceftriaxone and cefixime antibiotics are based on length of stay, ie 3–4; 3,125–5; 3,667–6 days. The use of chloramphenicol, ceftriaxone and cefixime antibiotics are based on the duration of fever, ie 1–2; 1,625–3,667; 1-2,667 days. ICER value in Seruni Utama showed that the usage of chloramphenicol required an additional cost of Rp. 91.382,72 to reduce one day of hospitalization compared to cefixime. ICER value in Seruni 1 showed that the usage of chloramphenicol required an additional cost of Rp. 51.018,575 to reduce one day of hospitalization compared to cefixime and Rp. 587.358,81 to reduce one day of fever compared to ceftriaxone. ICER value in Seruni 2 showed that the usage of ceftriaxone required an additional cost of Rp. 118.760,74 to reduce one day of hospitalization and Rp. 374.498,22 to reduce one day of fever compared to cefixime. ICER value in Seruni 3 showed that the usage of chloramphenicol required an additional cost of Rp. 664.304,50 to reduce one day of hospitalization and Rp. 1.650.777,72 to reduce one day of fever compared to cefixime. The usage of chloramphenicol is more cost-effective in Seruni Utama, 1 and 3 and ceftriaxone is more cost-effective in the Seruni 2.

Page 1 of 1 | Total Record : 1

 1 

Filter by Year

2019 2019


Reset
Filter By Issues
All Issue Vol. 10 No. 2 (2025) Vol. 10 No. 1 (2024) Vol. 9 No. 2 (2024) Vol. 9 No. 1 (2023) Vol. 8 No. 2 (2023) Vol. 8 No. 1 (2022) Vol. 7 No. 2 (2022) Vol. 7 No. 1 (2021) Vol. 6 No. 2 (2021) Vol 6, No 1 (2020) Vol. 6 No. 1 (2020) Vol 5, No 2 (2020) Vol 5, No 1 (2019) Vol. 5 No. 1 (2019) Vol 4, No 2 (2019) Vol 4, No 1 (2018) Vol 3, No 2 (2018) Vol 3, No 1 (2017) Vol 2, No 2 (2017) Vol 2, No 1 (2016) More Issue